Healthymagination Day, Tokyo 2010 GE Healthcare is seen as a leader in diagnostic imaging for the detection of cancer and as a leading provider of technologies for cancer research and biopharmaceutical manufacturing. In recent years, the company has significantly expanded its presence in the oncology arena through strategic acquisitions, including Amersham plc. (2004), Biacore International AB (2006), Wave Biotech LLC (2007), MicroCal LLC (2008), Clarient (2010) and Applied Precision (2011) and a joint venture Omnyx (2009). A recognized pioneer of oncology invention for over 50 years, GE Healthcare continues to research and develop industry-defining technologies. Courtesy of GE Healthcare

Chalfont St. Giles, UK - September 15, 2011

GE Healthcare, the health business of General Electric (NYSE: GE), announced today its plans to dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of biopharmaceuticals and for cancer research.

Courtesy of GE Healthcare

Announced alongside a $100m open innovation challenge in New York City, the $1 billion investment crosses all lines of GE Healthcare’s global business and is an example of the company’s commitment to fighting cancer.

The outer edges of the Discovery MR750w are designed to convey the feeling of being in safe hands. Courtesy of GE Healthcare

The investment will enable the company to bring the most promising cancer ideas to market, unleashing technologies that improve accuracy of diagnosis to enable more effective treatment decisions and empower doctors and patients with better information.

John Dineen, President & CEO, GE Healthcare. Hospital Efficiency Summit 2010 Courtesy of GE Healthcare

“We are committed to tackling cancer. However, with a disease as complex and multifaceted as cancer, solutions need to be equally multifaceted and even more integrated, combining imaging, molecular diagnostics and healthcare IT,” said John Dineen, president and CEO, GE Healthcare.
“As one of the most relevant global cancer diagnostic companies, we are devoting an even greater share of our R&D budget to continue developing new oncology solutions.”

Inspiring the Next Generation of Scientists Courtesy of GE Healthcare

Today, GE Healthcare already offers a wide portfolio for oncology and a strategy that combines cellular research, medical imaging, laboratory diagnostics, biopharmaceutical manufacturing technologies and information technology.

Inspiring the Next Generation of Scientists Courtesy of GE Healthcare

These innovative technologies help researchers increase their understanding of the causes and progression of cancer and help physicians make more personalized cancer treatment and management decisions, while improving clinical outcomes and accelerating the delivery of care.

Inspiring the Next Generation of Scientists Courtesy of GE Healthcare

A key global healthcare challenge is the dramatic increase in cancer incidence around the world.

According to World Health Organization data, cancer rates could increase by 50 percent, leading to 15 million new cases in 2020.

GE Healthcare’s award-winning Vscan handheld ultrasound device. Courtesy of GE Healthcare

From a clinical standpoint, the rapid increase in targeted and patient-specific cancer therapies is driving demand for molecular diagnostics.

Building a ‘Deeper Bench’ of Oncology Expertise

GE Healthcare is seen as a leader in diagnostic imaging for the detection of cancer and as a leading provider of technologies for cancer research and biopharmaceutical manufacturing.

Radiologists, there is an iPhone app for you too! Courtesy of GE Healthcare

In recent years, the company has significantly expanded its presence in the oncology arena through strategic acquisitions, including Amersham plc. (2004), Biacore International AB (2006), Wave Biotech LLC (2007), MicroCal LLC (2008), Clarient (2010) and Applied Precision (2011) and a joint venture Omnyx (2009).

Radiologists, there is an iPhone app for you too! Courtesy of GE Healthcare

A recognized pioneer of oncology invention for over 50 years, GE Healthcare continues to research and develop industry-defining technologies.

This work is happening at a fast pace across the company, in close collaboration with GE Global Research and through a number of strategic partnerships and alliances.

Radiologists, there is an iPhone app for you too! Courtesy of GE Healthcare

Of the imaging tools available to help oncologists manage a patient’s complete cancer pathway, there are few that offer as much clinical versatility and value as Positron Emission Tomography (PET)/Computed Tomography (CT).

Radiologists, there is an iPhone app for you too! Courtesy of GE Healthcare

Combining functional and anatomical data in a single image, PET/CT excels in early diagnosis, uncovering valuable information on tumor location, size and metabolic activity.

Radiologists, there is an iPhone app for you too! Courtesy of GE Healthcare

It assists physicians in differentiating between malignant and benign lesions, identifying recurrences and metastases, and guiding treatment selection and delivery.

Radiologists, there is an iPhone app for you too! Courtesy of GE Healthcare

The GE Healthcare Discovery PET/CT systems are designed to optimize the full range of oncology applications, from diagnosis and staging to treatment planning and monitoring.

Their versatility presents an ideal solution for multi-use and shared services, and across the patient care cycle.

Radiologists, there is an iPhone app for you too! Courtesy of GE Healthcare

GE Healthcare is introducing new tracers to the FASTlab multi-tracer platform, an advanced PET chemistry system on which the company is also developing PET proprietary agents.

FASTlab offers a number of significant enhancements to address the ever-evolving challenges of tracer production.

Investing in Invention

“The only way we can help clinicians beat cancer is to give them the tools to find it earlier, stage it better, and quantitatively measure response to therapy,” said GE Vice President and GE Healthcare Chief Technology Officer Mike Harsh, who oversees GE Healthcare’s global research and development efforts.
“The integration of GE Healthcare’s expertise in imaging, analytics, diagnostics, cellular analysis, and healthcare IT is helping create technologies and solutions that can be used in a rural developing country or in a modern urban hospital.”

The investment will focus on developing new oncology solutions and build on advanced technologies and research already in progress.

• New biomarkers:
A leader in the fast-growing in vitro molecular diagnostic sector, GE’s Clarient business provides diagnostic tests that pathologists and oncologists use to understand the nature of a cancer.

Clarient is investigating a new biomarker, TLE3, to identify patients who will not respond to Taxane. The goal of this test is to help clinicians exclude those patients from this therapy who are least likely to benefit, thus saving them needless exposure to serious side effects. TLE3 is being developed for breast cancer, lung cancer and ovarian cancer by GE Clarient. This will potentially save healthcare systems millions of dollars each year, not to mention the benefits to patient care. Our hope is to have these tests ready for market launch in 2013.

• Molecular pathology:
GE Global Research scientists are working on an exclusive cancer diagnostic technology that may give a clearer picture of pathways driving specific tumors. This may lead to more effective, personalized treatment recommendations. Called multiplexing, the technology could allow pathologists to conduct more than 50 different stains on a single tissue section.

• Cancer research:
GE’s innovative technologies for Life Science research are used in cancer research laboratories worldwide to advance understanding of the molecular mechanisms behind cancer. GE Healthcare’s cellular and sub-cellular imaging technologies, such as the IN Cell 6000 and Applied Precision’s super-resolution microscopes, are central to many areas of cancer research including drug discovery and biomarker research.

• Biopharmaceutical manufacturing:
GE’s world-class biotechnology products and services are used in the manufacture of the majority of FDA-approved biopharmaceuticals and are important for developing new and targeted cancer therapies.

• Hyperpolarizer:
In collaboration with the University of California, San Francisco (UCSF), GE Healthcare and GE Global Research are developing new C13-based agents for metabolic imaging. University researchers have just announced groundbreaking results from a study of prostate cancer utilizing GE's C13 technology, where real-time metabolic imaging of a human patient was conducted for the first time. A member of the UCSF research team describes it as a groundbreaking approach to understanding the precise margins of a tumor, how fast the tumor is growing and how well it responds to treatment.

• Connected oncology workflow:
MD Connect is a new, innovative thin-client solution designed for oncology that addresses the need for a seamless workflow from scan to plan through monitoring treatment effectiveness. MD Connect helps improve productivity across the cancer care continuum. Powered by the GE AW Server, it enables plug-and-play access via virtually any networked computer to the complete suite of oncology applications from any location or department. MD Connect integrates with the Eclipse™ treatment planning platform from Varian Medical Systems, all on one desktop and other DICOM-based treatment planning platforms.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.

Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world.

Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE).

Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.

For more information about GE Healthcare, visit our website at

www.gehealthcare.com  

For our latest news, please visit

http://newsroom.gehealthcare.com  


Press contacts

Sebastien Duchamp
GE Healthcare, Director Communications
+33 1 30 70 40 40
sebastien.duchamp@ge.com  

Allison Cohen
GE Healthcare
972 048579290
972 0547299742(mobile)
allison.cohen@ge.com  


Source: GE

http://www.genewscenter.com/content/default.aspx?newsareaid=2  


Video
GE Healthcare Puts $1B Towards Cancer R&D

http://www.youtube.com/watch?v=kL5yTxu9QWc&feature  



ASTROMAN Magazine – 2011.09.12

WellPoint and IBM Announce Agreement to Put Watson to Work in Health Care

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1056  


ASTROMAN Magazine – 2011.08.28

Saskatchewan and Hitachi Sign R&D Agreement on Nuclear Medicine Technology

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1044  


ASTROMAN Magazine – 2011.08.21

IBM Unveils Cognitive Computing Chips

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1042  


ASTROMAN Magazine – 2011.08.06

IBM Develops Full-text Digitization System for National Diet Library of Japan

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1027  


ASTROMAN Magazine – 2011.07.11

GE Healthcare Wins Design Excellence Awards for Magnetic Resonance Imaging

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1017  


ASTROMAN Magazine – 2011.06.04

GE Healthcare Opens Life Sciences Demonstration Laboratory in Stockholm, Sweden

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=986  


ASTROMAN Magazine – 2011.04.30

Metropolitan Chicago Healthcare Council to Develop Nation's Largest Metro Health Information Exchange

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=959  


ASTROMAN Magazine – 2011.04.28

Microsoft Implements Chronic Condition Management Platform at Denver Health

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=958  


ASTROMAN Magazine – 2011.04.07

Verizon and MEDfx Demonstrate Digital Exchange of Health Care Records

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=935  


ASTROMAN Magazine – 2011.03.31

Micromedex CareNotes Available Within the Iatric Systems Patient Discharge Module

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=931  


ASTROMAN Magazine – 2011.03.13

Department of Energy Finalizes $50 Million Loan for Vehicle Production Group

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=918  


ASTROMAN Magazine – 2011.02.20

IBM to Collaborate with Nuance to Apply IBM's "Watson" Analytics Technology to Healthcare

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=899  


ASTROMAN Magazine – 2011.01.23

Siemens Healthcare unveils the world's first integrated whole-body molecular MR system available for clinical use

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=887  


ASTROMAN Magazine – 2011.01.10

IBM and the Premier Healthcare Alliance to Integrate Nation's Healthcare Data

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=879  


ASTROMAN Magazine – 2011.01.08

Sanofi-aventis appoints New Senior Managers in Emerging Markets

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=875  


ASTROMAN Magazine – 2010.12.25

Accuray Establishes Medical Affairs Function to accelerate CyberKnife

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=862  


ASTROMAN Magazine – 2010.12.18

Andrew Witty appointed Lead Non-Executive Board Member for the Department for Business, Innovation and Skills

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=859  


ASTROMAN Magazine – 2010.12.18

GlaxoSmithKline partnerem "Koalicji na rzecz odpowiedzialnego biznesu"

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=858  


ASTROMAN Magazine – 2010.12.11

33rd Annual CTRC-AACR Breast Cancer Symposium

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=856  


ASTROMAN Magazine – 2010.12.11

GlaxoSmithKline: Data from Tykerb investigational phase III studies

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=854  


ASTROMAN Magazine – 2010.12.11

Combination Therapy Reduced HER2-positive Breast Cancers

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=855  


ASTROMAN Magazine – 2010.12.05

Impact Investing Emerges as a Distinct Asset Class

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=851  


ASTROMAN Magazine – 2010.12.04

Grand Prix INNOVA 2010 w Brukseli dla ITAM Zabrze

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=849  


ASTROMAN Magazine – 2010.11.20

Valeant Launches $700 million Senior Notes Offering

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=845  


ASTROMAN Magazine – 2010.11.07

New AT&T ForHealth Practice Accelerates Pursuit of $34 Billion

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=840  


ASTROMAN Magazine – 2010.08.29

Klub Wielkich Darczyńców

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=794  


ASTROMAN Magazine – 2010.05.20

CaridianBCT Releases Red Blood Cell Exchange Protocol in Canada

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=721  


ASTROMAN Magazine – 2010.04.18

Fujitsu and TUM Develop World's First DNA-based Revolutionary Bio-Sensor Technology

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=703  


ASTROMAN Magazine – 2010.03.27

Polacy opracowali nowatorski czujnik wykrywający melaminę

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=686  


ASTROMAN Magazine – 2010.01.16

CircleBath, opening of the first hospital designed by Foster + Partners

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=643  


ASTROMAN Magazine – 2010.01.14

Y chromosomes evolving rapidly

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=640  


ASTROMAN Magazine – 2009.12.23

Canon Inc. to make OPTOPOL Technology S.A. of Poland a subsidiary

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=624  


ASTROMAN Magazine – 2009.09.05

Toshiba's Aquilion ONE Honored With Medical Design Excellence Gold Award

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=568